In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
23 authors.
Marcel WeinreichSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, UK.
Harry McDonoughSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, UK.
Nancy YacovzadaDepartment of Molecular Genetics and Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-5152-8775 Iddo MagenDepartment of Molecular Genetics and Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-3011-3175 Yahel CohenDepartment of Molecular Genetics and Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-8628-5769 Calum HarveySheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, UK.ORCID 0000-0001-5033-9385 Sarah GornallSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, UK.
Sarah BoddySheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, UK.
Julian M KurzSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, UK.
Kevin P KennaDepartment of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.
Sai ZhangDepartment of Epidemiology, University of Florida, Gainesville, FL, USA.
Alfredo IacoangeliKing's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Basic and Clinical Neuroscience, London, UK.ORCID 0000-0002-5280-5017 Ahmad Al-KhleifatKing's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Basic and Clinical Neuroscience, London, UK.ORCID 0000-0002-7406-9831 Michael P SnyderCenter for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-0784-7987 Esther HobsonSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, UK.ORCID 0000-0002-8497-2338 Ammar Al-ChalabiKing's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Basic and Clinical Neuroscience, London, UK.
Eran HornsteinDepartment of Molecular Genetics and Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-5534-1924 Pamela J ShawSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, UK.ORCID 0000-0002-8925-2567 Christopher McDermottSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, UK.ORCID 0000-0002-1269-9053 Johnathan Cooper-KnockSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, UK.ORCID 0000-0002-0873-8689 Funding
PRODUCTION CENTER FOR MAPPING REGULATORY REGIONS OF THE HUMAN GENOMEUM1HG009442 · NHGRI · STANFORD UNIVERSITY · PI SNYDER, MICHAEL P. · 2017 to 2021
$20.1MStanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5MSignature Protein Profiles to Identify AAAsP50HL083800 · NHLBI · STANFORD UNIVERSITY · PI CONNOLLY, ANDREW J · 2006 to 2010
$13.7MDNA Variants and AAA DiseaseR01HL101388 · NHLBI · STANFORD UNIVERSITY · PI TSAO, PHILIP S · 2010 to 2013
$1.6MMicroRNA Regulation of Nicotine Accelerated AAAsR01HL122939 · NHLBI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI TSAO, PHILIP S · 2014 to 2017
$1.4MUltra high throughput sequencer for sustaining and enhancing multi-scale genomic studiesS10OD025212 · OD · STANFORD UNIVERSITY · PI SNYDER, MICHAEL P. · 2018 to 2018
$600kNHGRI NIH HHS UM1 HG009442NHLBI NIH HHS P50 HL083800NHLBI NIH HHS R01 HL101388NHLBI NIH HHS R01 HL122939NIDDK NIH HHS P30 DK116074NIH HHS S10 OD025212Wellcome Trust
6 · The paper itselfAbstract
Time-to-event prediction is a key task for biological discovery, experimental medicine, and clinical care. This is particularly true for neurological diseases where development of reliable biomarkers is often limited by difficulty visualising and sampling relevant cell and molecular pathobiology. To date, much work has relied on Cox regression because of ease-of-use, despite evidence that this model includes incorrect assumptions. We have implemented a set of deep learning and spline models for time-to-event modelling within a fully customizable 'app' and accompanying online portal, both of which can be used for any time-to-event analysis in any disease by a non-expert user. Our online portal includes capacity for end-users including patients, Neurology clinicians, and researchers, to access and perform predictions using a trained model, and to contribute new data for model improvement, all within a data-secure environment. We demonstrate a pipeline for use of our app with three use-cases including imputation of missing data, hyperparameter tuning, model training and independent validation. We show that predictions are optimal for use in downstream applications such as genetic discovery, biomarker interpretation, and personalised choice of medication. We demonstrate the efficiency of an ensemble configuration, including focused training of a deep learning model. We have optimised a pipeline for imputation of missing data in combination with time-to-event prediction models. Overall, we provide a powerful and accessible tool to develop, access and share time-to-event prediction models; all software and tutorials are available at www.predictte.org.
Indexed as
machine learningpersonalised medicineTime-to-event prediction
Identifiers
PMID39091819
PMCPMC11291041
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390